IGC Pharma, Inc.
IGC Pharma, Inc. (IGC) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
igc · stock forecast · 2 analysts (3M) · FMP · updated Jun 9, 2026
Analyst Rating & Consensus
Based on 2 Wall Street analysts in the past 3 months
Buy
2 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$0.00
Consensus
$0.00
+0.0% upside
Low
$0.00
Median: $0 · Last Close: $0.30
Short-Term Price Prediction
Algorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-10 | $0.30 | ↑ 0.47% |
1-day model range: $0.3–$0.3. Peak: $0.3 (+0.47%).
Long-Term Stock Price Prediction
Annual stock price forecast · 2027 / 2028 / 2029 / 2030 / 2031
| Year | Avg Price | Change |
|---|---|---|
| 2027 | $0 | -49.6% |
| 2028 | $0 | -62.1% |
| 2029 | $0 | -66.8% |
| 2030 | $0 | -68.9% |
| 2031 | — | -69.9% |
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
BULLISH
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · IGC · Jun 9, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2026-04-08 | Ascendiant Capital | Maintains | Buy→Buy |
| 2026-02-23 | Ascendiant Capital | Maintains | Buy→Buy |
| 2025-12-09 | Ascendiant Capital | Maintains | Buy→Buy |
| 2025-08-26 | Ascendiant Capital | Maintains | Buy→Buy |
| 2025-03-06 | Alliance Global Partners | Maintains | Buy→Buy |
| 2025-02-24 | Ascendiant Capital | Maintains | Buy→Buy |
| 2024-12-05 | Ascendiant Capital | Maintains | Buy→Buy |
| 2024-09-03 | Ascendiant Capital | Maintains | Buy→Buy |
| 2024-07-29 | Ascendiant Capital | Maintains | Buy→Buy |
| 2024-06-21 | Ascendiant Capital | Maintains | Buy→Buy |
Wall Street analysts have recently issued updated ratings on IGC Pharma, Inc. (IGC) stock. Of the recent 10 rating actions, 0 were upgrades and 0 were downgrades. 2 analysts currently cover IGC.
Analyst Recommendation Trends
IGC analyst recommendation trends show stable buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 1 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$1M
↑ 22.2% YoY
Revenue Next Year
$1M
↑ 17.3% YoY
EPS This Year
$-0.21
EPS Next Year
$-0.10
↓ 52.1% YoY
EPS ForecastReported vs Estimated
Analysts forecast IGC EPS of $-0.21 for the current fiscal year, based on estimates from 1 analysts. The IGC revenue forecast is $1M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The IGC stock forecast is supported by two independent data sources: analyst consensus ratings from 2 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus IGC price target is $0.00 (+0.0% upside), with an analyst consensus of Buy.
The IGC short-term stock prediction for tomorrow is $0.30 (+0.47%). The IGC stock price prediction for 2027 estimates an average of $0. The IGC stock prediction for 2030 projects a range of $0–$0.
IGC Pharma, Inc. trades on AMEX under the ticker IGC. The IGC stock outlook for 2027 is broadly positive, supported by a Buy consensus among 100% of covering analysts.
Frequently asked questions
IGC forecast · 8 questionsAccording to 2 Wall Street analysts, the average 12-month IGC price target is $0.00, with a high forecast of $0.00 and a low of $0.00. The median price target is shown in the chart above when available. This implies +0.0% potential upside from the current price of $0.30.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.